

## **Characterisation of patient and treatment profiles of migraine patients treated with erenumab in routine clinical practice: Interim results from the SPECTRE study**

Charly Gaul (Migraene and Headache Clinic Koenigstein, Germany)

Mirja Koch (Novartis Pharma AG, Basel, Switzerland)

Caroline Baufeld (Novartis Pharma GmbH, Nuernberg, Germany)

Erenumab, a CGRP receptor antagonist, was the first monoclonal antibody approved for preventive migraine treatment. The SPECTRE study (characterisation of Prescription patterns in Episodic and Chronic migraine patients starting Treatment in a Reallife setting with Erenumab in Germany) aims to better understand patient profiles and treatment patterns for erenumab in Germany based on migraine characteristics and comorbidities. This non-interventional study is conducted at 139 centers in Germany and enrolled 572 adult migraine patients. Apart from a daily headache diary, the patient-reported-outcome (PRO) questionnaires HIT-6 and TSQM are documented at 3-month intervals.

Previous baseline analysis of a small proportion of patients showed that the majority of erenumab patients in this subgroup were women with chronic migraine, with a high proportion of psychiatric comorbidities. Here we expand this analysis to about 400 erenumab patients. Baseline characteristics, including monthly migraine days, prophylactic pretreatments and comorbidities, and 6-month follow-up data, including information from an app-based migraine diary and PRO data, will be presented.

SPECTRE will provide valuable insights into the use of erenumab in clinical practice in Germany, help characterize prescription patterns, patient profiles and analyse the respective therapy response. This will possibly allow for development of individual treatment strategies for each patient.